204 related articles for article (PubMed ID: 24157581)
21. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
Chihara D; Cheah CY; Westin JR; Fayad LE; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak LW; Wang ML; Romaguera JE
Br J Haematol; 2016 Jan; 172(1):80-8. PubMed ID: 26648336
[TBL] [Abstract][Full Text] [Related]
22. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
23. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
24. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
Luskin MR; Ganetsky A; Landsburg DJ; Loren AW; Porter DL; Nasta SD; Svoboda J; Luger SM; Frey NV
Br J Haematol; 2016 Jul; 174(2):332-4. PubMed ID: 26403537
[No Abstract] [Full Text] [Related]
25. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
McGregor BA; Brown AW; Osswald MB; Savona MR
Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
[TBL] [Abstract][Full Text] [Related]
26. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Verma D; O'Brien S; Thomas D; Faderl S; Koller C; Pierce S; Kebriaei P; Garcia-Manero G; Cortes J; Kantarjian H; Ravandi F
Cancer; 2009 Jan; 115(1):101-6. PubMed ID: 19090005
[TBL] [Abstract][Full Text] [Related]
27. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.
Brady V; Thosani S; Zhou S; Bassett R; Busaidy NL; Lavis V
Diabetes Technol Ther; 2014 Dec; 16(12):874-9. PubMed ID: 25321387
[TBL] [Abstract][Full Text] [Related]
28. Progressive paresthesia and weakness after intrathecal chemotherapy.
Marshall R; Gupta ND; Palacios E; Neitzschman HR
J La State Med Soc; 2008; 160(2):92-4. PubMed ID: 18681351
[TBL] [Abstract][Full Text] [Related]
29. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
Thomas DA; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister FB; Cabanillas FF; Murphy S; Keating MJ; Kantarjian H
J Clin Oncol; 1999 Aug; 17(8):2461-70. PubMed ID: 10561310
[TBL] [Abstract][Full Text] [Related]
30. Immunophenotypic analysis of adult patients with T-cell lymphoblastic lymphoma treated with hyper-CVAD.
Kato H; Yamamoto K; Kodaira T; Higuchi Y; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
Hematology; 2018 Mar; 23(2):83-88. PubMed ID: 28778131
[TBL] [Abstract][Full Text] [Related]
31. A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.
Kim SY; Park JH; Yoon SY; Cho YH; Lee MH
Cancer Chemother Pharmacol; 2018 Feb; 81(2):393-398. PubMed ID: 29294168
[TBL] [Abstract][Full Text] [Related]
32. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
Commander LA; Seif AE; Insogna IG; Rheingold SR
Br J Haematol; 2010 Aug; 150(3):345-51. PubMed ID: 20528871
[TBL] [Abstract][Full Text] [Related]
33. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
[TBL] [Abstract][Full Text] [Related]
34. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
Erkut N; Akidan O; Selim Batur D; Karabacak V; Sonmez M
Chemotherapy; 2018; 63(4):207-213. PubMed ID: 30304722
[TBL] [Abstract][Full Text] [Related]
35. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Thomas DA; O'Brien S; Cortes J; Giles FJ; Faderl S; Verstovsek S; Ferrajoli A; Koller C; Beran M; Pierce S; Ha CS; Cabanillas F; Keating MJ; Kantarjian H
Blood; 2004 Sep; 104(6):1624-30. PubMed ID: 15178574
[TBL] [Abstract][Full Text] [Related]
36. Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Schrappe M; Bleckmann K; Zimmermann M; Biondi A; Möricke A; Locatelli F; Cario G; Rizzari C; Attarbaschi A; Valsecchi MG; Bartram CR; Barisone E; Niggli F; Niemeyer C; Testi AM; Mann G; Ziino O; Schäfer B; Panzer-Grümayer R; Beier R; Parasole R; Göhring G; Ludwig WD; Casale F; Schlegel PG; Basso G; Conter V
J Clin Oncol; 2018 Jan; 36(3):244-253. PubMed ID: 29148893
[TBL] [Abstract][Full Text] [Related]
37. Primary T-cell lymphoblastic lymphoma of the cavernous sinus.
Sadruddin S; Medeiros LJ; DeMonte F
J Neurosurg Pediatr; 2010 Jan; 5(1):94-7. PubMed ID: 20043743
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of modified Hyper-CVAD regimen on non-Hodgkin's lymphoma and safety evaluation].
Shi W; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Dong M; Liu P; Qin Y; Yang S; Gui L; Lv Z
Ai Zheng; 2009 Oct; 28(10):1083-7. PubMed ID: 19799818
[TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.
Taylor CW; Dalton WS; Mosley K; Dorr RT; Salmon SE
Breast Cancer Res Treat; 1997 Jan; 42(1):7-14. PubMed ID: 9116320
[TBL] [Abstract][Full Text] [Related]
40. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM
Leuk Res; 2017 Sep; 60():58-62. PubMed ID: 28704720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
